Illumina shares fall 9.79% after hours as Q4 results fail to allay investor concerns over China challenges and.

Illumina (ILMN) fell 9.79% in after-hours trading following its Q4 2025 earnings report, despite beating revenue and EPS estimates. The decline reflects mixed guidance and ongoing challenges. While the company reported $1.16 billion in revenue (up 5% YoY) and non-GAAP EPS of $1.35, its 2026 revenue guidance of $4.5–4.6 billion—flat to slightly above 2024 levels—fell short of expectations for stronger growth. Ex-China organic revenue growth for 2026 was projected at 2–4%, below prior momentum. Persistent headwinds in China, including its placement on the Unreliable Entities List, and margin pressure from the SomaLogic acquisition (which added $0.18 dilution to EPS) further dampened sentiment. Investors appeared to prioritize cautious guidance and geopolitical risks over near-term results, driving the sharp after-hours sell-off.